Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Inhibition of Corneal Lymphangiogenesis and Angiogenesis after Low-risk Keratoplasty using VEGF TrapR1R2 improves Transplant Survival

Cursiefen C.1, Chen L.1, Jackson D.2, Rudge J.S.3, Wiegand S.J.3, Dana M.R.1, Streilein J.W.1
1
Dept. of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston/USA; 2Institute of Molecular Medicine Oxford, MRC Human Immunology Unit, Oxford/UK; 3Regeneron Pharmaceuticals Inc., Tarrytown/USA

Purpose: Neovascularization of the cornea occurs in about 50% of patients after low-risk corneal transplantation. We sought to determine whether inhibition of angiogenesis and lymphangiogenesis occurring after transplantation improves graft survival.
Method: Using the mouse model of low-risk corneal transplantation, C57BL6 donor grafts (diameter 2 mm) were placed in avascular recipient beds of BALB/c mice aged 6-8 weeks. One group of BALB/c mice was treated intraperitoneally with 12.5 mg/kg VEGF TrapR1R2 (a chimeric protein consisting of VEGF receptor 1 and 2 domains coupled to a Fc-fragment) on day 1 and 8 after transplantation or with human Fc-protein alone (control). Graft survival was evaluated using slit-lamp microscopy until week 8. Corneal blood and lymph angiogenesis were quantified by slit-lamp examination, and by immunofluorescence microscopy and morphometry using CD31 as a panendothelial and LYVE-1 as a lymphatic endothelial-specific marker.
Results: In mice treated wit


Zurück | Back